title: Alloantigen presentation and graft-versus-host disease: fuel for the fire.
abstract: Allogeneic stem cell transplantation (SCT) is a unique procedure, primarily in patients with hematopoietic malignancies, involving chemoradiotherapy followed by the introduction of donor hematopoietic and immune cells into an inflamed and lymphopenic environment. Interruption of the process by which recipient alloantigen is presented to donor T cells to generate graft-versus-host disease (GVHD) represents an attractive therapeutic strategy to prevent morbidity and mortality after SCT and has been increasingly studied in the last 15 years. However, the immune activation resulting in GVHD has no physiological equivalent in nature; alloantigen is ubiquitous, persists indefinitely, and can be presented by multiple cell types at numerous sites, often on incompatible major histocompatibility complex, and occurs in the context of intense inflammation early after SCT. The recognition that alloantigen presentation is also critical to the development of immunological tolerance via both deletional and regulatory mechanisms further adds to this complexity. Finally, GVHD itself appears capable of inhibiting the presentation of microbiological antigens by donor dendritic cells late after SCT that is mandatory for the establishment of effective pathogen-specific immunity. Here, we review our current understanding of alloantigen, its presentation by various antigen-presenting cells, subsequent recognition by donor T cells, and the potential of therapeutic strategies interrupting this disease-initiating process to modify transplant outcome.
authors.affiliation: QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; and.
authors.forename: Motoko
authors.initials: M
authors.lastname: Koyama
authors.affiliation: QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; and Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
authors.forename: Geoffrey R
authors.initials: GR
authors.lastname: Hill
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D006086:Graft vs Host Disease / Q000209:etiology* / Q000276:immunology; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007519:Isoantigens / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
chemical_list: D007519:Isoantigens